The Global Health Drug Discovery Institute (GHDDI) Licenses Scilligence ELN

The Global Health Drug Discovery Institute (GHDDI) has licensed Scilligence Electronic Laboratory Notebook (ELN). Scilligence ELN will help GHDDI to strength collaboration within the organization by digitalizing experimental data. GHDDI researchers are now able to easily search and organize their experiments and associated files

.About The Global Health Drug Discovery Institute (GHDDI)

The Global Health Drug Discovery Institute (GHDDI) identifies and develops innovative approaches to new medicines for diseases most damaging to populations in the developing world. Being the first independent, not-for-profit research institute of its kind in China, GHDDI strives to establish a transformative drug discovery and translational platform with advanced biomedical research and development capabilities – from the bench to the bedside. GHDDI is jointly founded by the Bill and Melinda Gates Foundation, Tsinghua University, and the Beijing Municipal Government, and is closely partnered with the California Institute for Biomedical Research (Calibr) in scientific research.

About Scilligence

Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in the discovery and development of small molecule and biologic therapeutics.

The first-ever integration between an electronic lab notebook (ELN) and a chemistry research database will rely on FAIR principles to improve experiments and reduce manual curation

Scilligence, a provider of cheminformatics and bioinformatics solutions for the life sciences industry, has selected Elsevier’s Reaxys to help chemists improve efficiency and productivity.

Chemists often begin their work by following a manual process, searching for information and transferring that information between platforms, then typing in experimental details from references – all before going into the lab to run an experiment. This cumbersome process can introduce errors at multiple points. The ELN-Reaxys integration will allow chemists to search Reaxys for reactions of interest via the Scilligence electronic lab notebook (ELN) and retrieve appropriate reaction information and relevant references into their ELN. This will eliminate the need to copy/paste or draw manually, helping chemists streamline this process, maintain greater levels of transparency and reduce time and errors.

“ELNs are designed to capture data, but they are not the most efficient tools when it comes to searching for literature references and associating that with experiments,” said Jinbo Lee, Chief Scientific Officer and Co-founder, Scilligence. “Many ELN users don’t have the tendency to include reference information in their experiments, making it very difficult for other team members to figure out how a synthesis idea was originated. By integrating Scilligence ELN’s informatics capabilities with Reaxys’ data, we can increase efficiency, improve cross-referencing, and reduce manual errors.”

Further, making data FAIR (Findable, Accessible, Interoperable and Reusable) is an industry-wide expectation. Elsevier is at the forefront of the adoption of FAIR principles, with several Elsevier officials participating in the framework’s original committee.

“We are in an era of unprecedented opportunities to translate breakthrough science discoveries into therapies,” said Ivan Krstic, Director, Chemistry Solutions, Elsevier, the information analytics company specializing in science and health. “Still, IT and data issues present imposing barriers. Many organizations have data siloed in different departments, solutions and formats, and every time chemists want to add a new component, tool or data set to their review they can waste a lot of time normalizing that data to make it usable. That’s why it’s essential, and beneficial, for ELNs to integrate seamlessly with reliable data sources, to eliminate inefficient processes and empower chemists to answer their most pressing questions.”

The Scilligence-Reaxys alliance will, in the near future, lower even further the barriers between these silos. The Unified Data Model (UDM) data format maintained by the Pistoia Alliance will be established as the standard data exchange format for reactions between the Scilligence ELN and Reaxys. Hence, chemists will be able to transfer data from Reaxys into the Scilligence ELN. Also, data exported from the Scilligence ELN can be incorporated into Reaxys, reducing the need for the user to establish data transformation processes.

Reaxys retrieves literature, compound properties and chemical reaction data faster than any other solution and, together with Reaxys Medicinal Chemistry (RMC), offers pharma companies a ‘one stop shop’ chemistry ecosystem thanks to its integration capabilities, innovative APIs, and bioactivity data. The Reaxys platform contains over 240 years of unparalleled chemistry content, including: 119 million organic, inorganic and organometallic compounds, 46 million chemical reactions, 500 million published experimental facts, 16,000 chemistry related periodicals, Asian, European and US patents, and six indexing sources for a cross-disciplinary view of chemistry. RMC offers access to data from a vast repository of peer-reviewed journal articles and patents and is interoperable with Reaxys www.elsevier.com/solutions/reaxys.

—

About Scilligence
Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in the discovery and development of small molecule and biologic therapeutics.

About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKeyand Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray’s Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com

Media contact

Christopher Capot, Global Communications
Elsevier
+1 917 704 5174
[email protected]

Originally posted by Elsevier: https://www.elsevier.com/about/press-releases/clinical-solutions/scilligence-and-elsevier-collaborate-to-enhance-lab-efficiency

Scilligence, a provider of mobile cheminformatics and bioinformatics for the life sciences industry, has joined the Accenture research platform open partner ecosystem, which will allow for the integration of Scilligence’s informatics solutions. Scilligence’s proprietary technologies address three main areas of R&D informatics needs: knowledge management and collaboration; project, workflow, and material management; and knowledge mining of unstructured data.

The research platform is an open partner ecosystem designed to help independent software vendors (ISVs) and life sciences companies collaborate more effectively to speed up drug discovery initiatives and enhance patient outcomes. Accenture’s project has been developed in collaboration with Merck and Amazon Web Services to enhance innovation and collaboration between life science companies and software providers. Scilligence is one of the first ISVs and organizations to integrate its technology and content into Accenture’s research platform.

“The Accenture research platform delivers an exciting cloud-based ecosystem for life sciences R&D informatics. Scilligence is proud to contribute to this platform,” said Jinbo Lee, CSO and co-founder of Scilligence.

Life science companies – such as pharmas, biotechs, contract research organizations, and research institutions – with a common informatics platform will have the ability to share their data more effectively and efficiently through the platform’s open application programming interface. This allows researchers to quickly access data and analyze data from multiple applications using a single interface in a secure and integrated environment. Scilligence provides cheminformatics and bioinformatics solutions to researchers easily and efficiently.

“The open partner ecosystem is one of the ways we’re bringing innovation to our clients through the Accenture research platform,” said Joe Donahue, a managing director in Accenture’s Life Sciences practice. “Through integration into the platform, users will gain access to Scilligence solutions that enhance knowledge sharing and productivity of researchers in discovery and development of small molecule and biologics therapeutics, which will ultimately lead to better patient outcomes.”

Click here to learn more about the Accenture Life Sciences research platform.

About Scilligence

Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in the discovery and development of small molecule and biologic therapeutics.

Contact
Krystyana Roman, Senior Marketing Specialist, Scilligence
[email protected]

Accenture has partnered with over 30 software vendors and other organizations to integrate their technology with Accenture’s research platform. Through this platform, vendors will have the opportunity to leverage the use of open, industry-standard application programming interfaces, enabling researchers to access innovative technologies. The ultimate goal of the project is to help life sciences organizations improve productivity, efficiency, and innovation in drug discovery R&D.

Scilligence is one of the vendors involved in this project and will join Accenture, Amazon, and Merck for a Research Platform Ecosystem integration workshop on November 28th from 8:00 – 10:30 AM during AWS re:Invent in Las Vegas. Accenture will demo Scilligence’s entity registration system and Scilligence will be a guest panelist during the event.

More information about the event and agenda can be found here: https://ti.to/rlsc/isv-workshop-las-vegas

The Pistoia Alliance, a global alliance of life science companies, vendors, publishers and academic groups, and Scilligence Corporation are pleased to announce the release of the major new extension to the HELM Web Editor. New functionalities enable the editor to support the representation of biomolecules with some structural uncertainty or ambiguity and also adds monomer and rule managers.

The therapeutic utilization of complex and unique biomolecules has become commonplace in drug discovery R&D. As a result, scientists have struggled to represent these entities in their informatics systems, forcing them to use various “pick and mix” approaches that include multiple nomenclatures and textual descriptions. HELM, the open biomolecular representation standard, has solved this problem by providing a means to represent various types of complex macromolecules (e.g. nucleotides, proteins, antibodies and antibody-drug conjugates) including the ones that contain unnatural amino acids or nucleotides/nucleosides.

The Pistoia Alliance formalized the HELM notation, originally developed by scientists at Pfizer, as an open standard in early 2013. The related toolkit and editor were later publicly released to the open source community. Since its release, HELM has been widely adopted by various organizations such as Bristol Myers Squibb, Pfizer, Novartis, Roche, GSK, Ionis, Merck and Co, Scilligence, NextMove Software, Dassault Systèmes BIOVIA, ChemAxon, Perkin-Elmer, quattro research, EMBL-EBI, NCBI (PubChem), and RDKit.

While the original HELM solved the problem of representing unnatural complex biomolecules, it held the basic assumption that a scientist would know everything about the structures being represented. In biology, however, this is not always the case, as various types of ambiguity or uncertainty may exist in some of these structures. A typical example is when the exact conjugation site of an antibody-drug conjugate cannot be determined. This left scientists with a difficult choice: either record the best guess of what the structure is or simply describe the structure textually instead of structurally, creating a gap in their corporate structural registries. This update to the web-editor enables scientists to incorporate into their structural representation a systematic description of a number of forms of ambiguity, thus allowing for the rigorous representation of structures, even when uncertainty is present.

“The HELM Web Editor already facilitates researchers’ ability to rigorously represent complex macromolecules in a technology-friendly manner. However, there was still a gap when it came to dealing with the very real-world scenario of structural uncertainty or ambiguity. Through this partnership with Scilligence, we have implemented the enhancements available in HELM 2.0 and further extended the capabilities and applicability of the open source tools,” said Sergio Rotstein, Director of Research Business Technology at Pfizer and Domain Lead for the Pistoia Alliance HELM initiative.

About Pistoia Alliance
The Pistoia Alliance is a global, not-for-profit members’ organization made up of life science companies, technology and service providers, publishers, and academic groups working to lower barriers to innovation in life science and healthcare R&D. It was conceived in 2007 and incorporated in 2009 by representatives of AstraZeneca, GSK, Novartis and Pfizer who met at a conference in Pistoia, Italy. Its projects transform R&D through pre-competitive collaboration. It overcomes common R&D obstacles by identifying the root causes, developing standards and best practices, sharing pre-competitive data and knowledge, and implementing technology pilots. There are currently over 80 member companies; members collaborate on projects that generate significant value for the worldwide life sciences R&D community, using the Pistoia Alliance’s proven framework for open innovation.
http://www.pistoiaalliance.org

About Scilligence
Scilligence is a leading innovator of web-based applications for life science research and development. Scilligence’s proprietary technologies provide a complete solution for all research informatics needs. Scilligence’s software tools enhance the knowledge sharing and productivity of researchers in discovery and development of small molecule and biologic therapeutics.
https://scilligence.com

Contact
Krystyana Roman, Marketing Specialist, Scilligence
[email protected]
+1 (617) 520-4588

 Claire Bellamy, Project Manager, Pistoia Alliance
[email protected]
+44 7823 470513

CAMBRIDGE, Massachusetts – Scilligence, an innovative and sought-after integrated informatics software provider for life science R&D, has made it its mission is to deliver quality solutions globally. The company has already established offices in Europe and Asia and is expecting continued growth in these markets.

In addition to its team expansion, Scilligence now offers clients the option to host their informatics solutions on the cloud with a choice of data centers located in the United States (East and West Coast), Europe, Japan, China, and Singapore. The option to choose client’s own data center, not only offers Scilligence global customers the flexibility in terms of data hosting, but also ensures customers that data storage and management are in compliant with any local/regional regulatory as required.Scilligence offers independent deployment for each customer’s unshared data, which, guarantees IP protection and security. Scilligence has recently been awarded the ISO-27001:2013 certification, meeting the requirements of a world-class information security management system and once again ensuring client’s protection of its intellectual property and data.About ScilligenceScilligence is a leading innovator of web-based applications for life science research and development. Scilligence’s proprietary technologies provide a complete solution for R&D informatics needs. Scilligence’s software tools enhance the knowledge sharing and productivity of researchers in discovery and development of small molecule and biologic therapeutics.https://scilligence.com

---

Scilligence has been awarded the ISO-9001:2015 and ISO-27001:2013 Certification for Design and Development of Web-based Cheminformatics and Bioinformatics Solutions.

The ISO 9001: 2015 certification has been awarded to Scilligence for meeting the criteria of a quality management system. The certification is based on principles such as a strong customer focus, dedication to constant improvement, implementing a top management system, and consistently meeting client requirements.

Scilligence received the ISO-27001:2013 for meeting the requirements of an information security management system and ensuring that client intellectual property and data remain secure and protected.

These levels of certification prove Scilligence’s constant commitment to quality and customer satisfaction.

About Scilligence
Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in discovery and development of small molecule and biologic therapeutics.

About Internation Organization for Standardization (ISO)
ISO is an independent, non-governmental and international organization, dedicated to developing standards to ensure efficiency, quality, and safety for products, services, and systems.
www.iso.org

The State Key Laboratory of Natural and Biomimetic Drugs at Peking University has licensed RegMol and Scilligence Inventory systems. This state-of-the-art informatics platform will centralize data and sample management, and facilitate collaborations at the State Key Laboratory.

About Scilligence
Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in discovery and development of small molecule and biologic therapeutics.

The State Key Laboratory of Natural and Biomimetic Drugs at Peking University
The State Key Laboratory of Natural and Biomimetic Drugs, established in 1985, consists of an award-winning staff and multiple research groups making strides in a wide-range of disciplines including synthetic medicinal chemistry, natural drug, pharmacology, pharmaceutics, and more. The laboratory focuses on both fundamental and applied research in natural and biomimetic drugs to help tackle major diseases, such as tumors, cardio-cerebrovascular diseases, mental illnesses and viral infections. The laboratory accomplished the improbable in the fields of nucleic acid chemistry, carbohydrate chemistry, glycobiology, bioinorganic chemistry, natural product, and Chinese herbal medicine and has passed four assessments organized by the Ministry of Science and Technology with favorable results.

The Institute of Medicinal Plant Development (IMPLAD) has licensed Scilligence’s TouchMol4Office, a cheminformatics and bioinformatics plug-in for Microsoft Office. This informatics tool will significantly enhance researchers’ ability to analyze and visualize chemical compositions of natural products in medicinal herbs.

About Scilligence
Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in discovery and development of small molecule and biologic therapeutics.

About The Institute of Medicinal Plant Development
The Institute of Medicinal Plant Development (IMPLAD), and Beijing Medicinal Plant Garden, affiliated with the Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), was established in August 1983. The headquarters are located in Zhongguancun Scientific and Technical Zone, Beijing, with six branches respectively distributed in Yunan, Hainan, Guangxi, Xinjiang, Chongqing, and Guizhou. As the only one national research institution of public service specializing in protection, development, and utilization of medicinal plant resources, and also one of the well-known institutions focusing on medicinal plant research worldwide, IMPLAD is playing a leading role in research on Chinese medicinal herbs, and has been working as WHO Collaborating Center for Traditional Medicine.

The Pistoia Alliance and Scilligence Corporation are pleased to announce the release of the HELM (Hierarchical Editing Language for Macromolecules) Web Editor, which brings HELM’s industry standard biomolecular representation to the browser, greatly enhancing the deployability of the technology for its adopters.

As the therapeutic utilization of complex and unique biomolecules has become commonplace in drug discovery R&D, scientists have struggled to represent these entities in their information systems, forcing them to use various “pick and mix” approaches that include multiple nomenclatures and textual descriptions. HELM, the open biomolecular representation standard, has solved this problem by providing a means to represent various types of complex macromolecules (e.g. nucleotides, proteins, antibodies and antibody-drug conjugates) including those that contain non-natural elements such as chemically modified amino acids.

The Pistoia Alliance formalized the HELM notation, originally created by Pfizer scientists as an open standard in early 2013, and publicly released the related software toolkit and editor to the Open Source community. Since its release, HELM has benefited from a growing ecosystem of global adopters and contributors including organizations such as Bristol Myers Squibb, Pfizer, Novartis, Roche, GSK, Ionis, Merck and Co, Scilligence, NextMove Software, ACD/Labs, Arxspan, BioChemfusion, Dassault Systèmes BIOVIA, ChemAxon, Perkin-Elmer, quattro research, EMBL-EBI, NCBI (PubChem), and RDKit.

While the original HELM Applet editor, supporting HELM Notation 1.0 and developed using Java, made it easier for scientists to draw and view macromolecules, technology evolved, leaving the applet unsupported by many browsers. The new HELM Web Editor is completely built on JavaScript, which removes dependencies and increases the compatibilities with modern browsers.

2017 will see further updates to the web editor to add monomer and ruleset management, support for the HELM 2.0 ambiguity features and antibody editing.

As major contributors to this project, Novartis AG and Ionis Pharmaceuticals are adopting the new HELM Web Editor.

Dr. Eric Swayze, Vice President of Chemistry and Neuroscience Drug Discovery at Ionis Pharmaceuticals adds: “The new HELM Web Editor makes it easier for our scientists to adopt the HELM technologies, which helps them to more efficiently represent and register complex chemically modified biomolecules, which facilitates exchange of information within the team.”

Dr. Jinbo Lee, CSO of Scilligence adds: “We appreciate the opportunity working on the project. The new HELM Web Editor’s zero-footprint and enhanced usability will help the scientific community including life-science, academic, and technology organizations adopt the HELM standard.”

About Pistoia Alliance
The Pistoia Alliance is a global, not-for-profit members’ organization made up of life science companies, technology and service providers, publishers, and academic groups working to lower barriers to innovation in life science and healthcare R&D. It was conceived in 2007 and incorporated in 2009 by representatives of AstraZeneca, GSK, Novartis and Pfizer who met at a conference in Pistoia, Italy. Its projects transform R&D through pre-competitive collaboration. It overcomes common R&D obstacles by identifying the root causes, developing standards and best practices, sharing pre-competitive data and knowledge, and implementing technology pilots. There are currently over 80 member companies; members collaborate on projects that generate significant value for the worldwide life sciences R&D community, using the Pistoia Alliance’s proven framework for open innovation.
www.pistoiaalliance.org

About Scilligence
Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in discovery and development of small molecule and biologic therapeutics.
www.scilligence.com

Contact
Krystyana Roman, Marketing Specialist, Scilligence.
[email protected]
+1 (617) 520-4588

Claire Bellamy, Project Manager, Pistoia Alliance
[email protected]
+44 7823 470513

Read on Pistoia Alliance’s site